Compare Abbott India with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs NATCO PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA NATCO PHARMA ABBOTT INDIA/
NATCO PHARMA
 
P/E (TTM) x 44.7 15.5 287.8% View Chart
P/BV x 12.8 3.1 419.8% View Chart
Dividend Yield % 0.5 1.5 36.9%  

Financials

 ABBOTT INDIA   NATCO PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
NATCO PHARMA
Mar-18
ABBOTT INDIA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1101,080 565.7%   
Low Rs3,996671 595.3%   
Sales per share (Unadj.) Rs1,552.2592.1 262.2%  
Earnings per share (Unadj.) Rs188.8188.4 100.2%  
Cash flow per share (Unadj.) Rs196.4206.3 95.2%  
Dividends per share (Unadj.) Rs55.008.25 666.7%  
Dividend yield (eoy) %1.10.9 115.5%  
Book value per share (Unadj.) Rs796.6833.6 95.6%  
Shares outstanding (eoy) m21.2536.90 57.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.31.5 220.1%   
Avg P/E ratio x26.84.6 575.8%  
P/CF ratio (eoy) x25.74.2 606.2%  
Price / Book Value ratio x6.31.1 603.9%  
Dividend payout %29.14.4 665.2%   
Avg Mkt Cap Rs m107,37632,311 332.3%   
No. of employees `0003.34.8 68.8%   
Total wages/salary Rs m3,9373,256 120.9%   
Avg. sales/employee Rs Th9,929.34,522.5 219.6%   
Avg. wages/employee Rs Th1,185.1674.0 175.8%   
Avg. net profit/employee Rs Th1,207.71,439.0 83.9%   
INCOME DATA
Net Sales Rs m32,98521,848 151.0%  
Other income Rs m1,170404 289.6%   
Total revenues Rs m34,15522,252 153.5%   
Gross profit Rs m5,2459,284 56.5%  
Depreciation Rs m162662 24.5%   
Interest Rs m38154 24.8%   
Profit before tax Rs m6,2158,872 70.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2031,920 114.7%   
Profit after tax Rs m4,0126,952 57.7%  
Gross profit margin %15.942.5 37.4%  
Effective tax rate %35.421.6 163.8%   
Net profit margin %12.231.8 38.2%  
BALANCE SHEET DATA
Current assets Rs m22,65521,307 106.3%   
Current liabilities Rs m6,6815,920 112.9%   
Net working cap to sales %48.470.4 68.8%  
Current ratio x3.43.6 94.2%  
Inventory Days Days6573 88.4%  
Debtors Days Days29107 27.4%  
Net fixed assets Rs m83514,986 5.6%   
Share capital Rs m213369 57.6%   
"Free" reserves Rs m16,71530,353 55.1%   
Net worth Rs m16,92830,760 55.0%   
Long term debt Rs m00-   
Total assets Rs m24,16237,151 65.0%  
Interest coverage x163.758.6 279.3%   
Debt to equity ratio x00-  
Sales to assets ratio x1.40.6 232.1%   
Return on assets %16.819.1 87.6%  
Return on equity %23.722.6 104.9%  
Return on capital %36.929.3 125.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36910,322 3.6%   
Fx outflow Rs m3,8072,978 127.8%   
Net fx Rs m-3,4387,343 -46.8%   
CASH FLOW
From Operations Rs m1,5274,636 32.9%  
From Investments Rs m-2,148-11,155 19.3%  
From Financial Activity Rs m-1,0246,509 -15.7%  
Net Cashflow Rs m-1,646-18 9,142.2%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 7.9 7.8 100.8%  
FIIs % 0.1 16.6 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 26.0 65.8%  
Shareholders   18,270 25,395 71.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS